Patient who is pregnant and/or breastfeeding
292.0
Pregnant or lactating women
545.0
Woman who are pregnant or breastfeeding
128.0
TREATMENT: Pregnant
44.0
Pregnant or breastfeeding
90.0
Pregnant women are eligible to participate in this study
612.0
Females who are pregnant or breastfeeding are ineligible
450.0
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
140.0
Breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
72.0
Pregnant women are excluded from this study
72.0
TUMOR BIOPSY SEQUENCING: Women who are pregnant or breastfeeding
700.0
TREATMENT: Breastfeeding should be discontinued while the patient is on this trial and for 30 days following last dose of study drug
700.0
TREATMENT: Women who are pregnant or breastfeeding
700.0
Women who are pregnant or breastfeeding
92.0
Pregnant and breastfeeding women are excluded from this study
100.0
Pregnant women are excluded from this study; breastfeeding should be discontinued
28.0
Pregnant or breastfeeding women
1500.0
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
24.0
Pregnant women are excluded; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
35.0
If pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-3475
36.0
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with dabrafenib/trametinib
18.0
Pregnant women and women who are breastfeeding are excluded from this study
46.0
Pregnant women are excluded from this study; breastfeeding should be discontinued
45.0
Pregnant women are excluded from this study
37.0
Not pregnant or nursing, with negative serum pregnancy test; pregnant women are excluded from this study; breastfeeding should be discontinued; timeline: within 3 weeks prior to enrollment
18.0
Pregnant women
348.0
Pregnant women and women who are breastfeeding are excluded from this study
60.0
